Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

F Rossi, L Prosperini, N. De Rossi, Ruggero Capra, D Rivanera, X Li, P Cinque, Laura Passeri, Carlo Pozzilli, R Viscidi

Research output: Contribution to journalArticlepeer-review

Abstract

To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML. © Copyright 2017, Mary Ann Liebert, Inc. 2017.
Original languageEnglish
Pages (from-to)622-626
Number of pages5
JournalViral Immunology
Volume30
Issue number8
DOIs
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy'. Together they form a unique fingerprint.

Cite this